Progenics Pharma (PGNX) Misses Q3 EPS by 1c

Progenics Pharma (NASDAQ: PGNX) reported Q3 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $2.35 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Arrive AI and DXC Technology partner to bring delivery tech to factories
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold